Healthcare
FDA revises biosimilar guidelines for clearer drug labelling
The FDA released a draft guidance giving advice on the correct labelling of biosimilar and interchangeable biosimilar products.
NHS doubles down on Netflix-style antibiotic subscription model
Unmet needs remain in treatment of triple negative breast cancer
US announces measures to reduce healthcare costs
Prescription drug costs for NHS rise by 8% to £10.4bn in England
FDA proposes new model for easy-to-understand prescription guides
